Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.

Significance of targeting DNMT3A mutations in AML

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

DNMT3A Gene Mutations in Acute Myeloid Leukemia——Review

DNMT3A gene mutations in acute myeloid leukemia]

Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Molecular and clinical significance of FLT3, NPM1, DNMT3A and TP53 mutations in acute myeloid leukemia patients

Role of DNA methyltransferase 3A in hematological malignancies

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Targeted Treatment of Acute Myeloid Leukemia Based on Epigenetic Regulation Mechanism

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

Epigenetic Landscape Analysis of Lncrnas in Acute Myeloid Leukemia with DNMT3A Mutations.

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS

DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming

DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction Between EZH2 and DNMT3A.

NAM-NAD+-ADO metabolic reprogramming is a key factor for DNMT3A mutation to promote leukemia development through regulating cell cycle and immune microenvironment

WT1 And DNMT3A Mutations in Prognostic Significance of Acute Myeloid Leukemia: A Meta-Analysis

The Incidence of DNA Methyltransferase 3 Alpha(dnmt3a)gene Mutation in Patients with Acute Myeloid Leukemia(aml)and Its Clinical Significance

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia